Hospital Acquired Pneumonia

Slide 1 · Hospital-Acquired Pneumonia

Etiology • pulmonary defenses • morphology • diagnosis

Clinicopathologic lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Recognize HAP and VAP using an explicit clinical timeline.

Explain how impaired pulmonary defenses and hospital exposures predispose to infection.

Relate key bacterial pathogens to acute suppurative lung morphology.

Integrate microbiology, imaging, and clinical findings; Recognize diagnostic uncertainty.

Explain major complications and antimicrobial stewardship principles.

Slide 3 · Pneumonia is infection of lung parenchyma

A clinical syndrome rather than a single pathogen-defined disease.

Inflammation of bronchioles and alveoli may impair gas exchange.

Host susceptibility, inoculum, and microbial features shape presentation.

Hospital onset changes the likely organisms and the resistance profile.

Core pathology

Intra-alveolar inflammatory exudate explains consolidation in acute bacterial pneumonia.

Slide 4 · Hospital-acquired pneumonia: Defining feature

New pulmonary infection arising during a hospital stay.

Clinical definition (ATS/IDSA 2016): Not incubating on admission; Onset ≥48 h after admission.

In contemporary ATS/IDSA guidance, “HAP” is used for pneumonia unrelated to mechanical ventilation.

Hospital-acquired infection may worsen an illness that prompted admission.

Slide 5 · HAP versus VAP: Use the clock

Admission

Establish baseline symptoms and imaging

≥48 h in hospital

New infection in a non-ventilated patient: HAP

Intubation

Mechanical ventilation introduces a second clock

>48 h after intubation

Pneumonia in a ventilated patient: VAP

Definitions are clinical conventions; Neither interval alone proves infection.

Slide 6 · Clinical setting modifies the differential

Setting

Practical interpretation

Typical emphasis

Community onset

Consider community-acquired pathogens

Not automatically a nosocomial infection

HAP: non-ventilated

Hospital-onset pneumonia after 48 h

S. aureus, gram-negative bacilli

VAP

Pneumonia after >48 h of intubation

Similar spectrum; more gram-negative bacilli

Aspiration-related

Entry of oral/gastric contents

Mechanism differs; bacterial overlap possible

Slide 7 · “Healthcare-associated pneumonia”: Terminology caution

The source chapter discusses healthcare-associated pneumonia (HCAP) as a separate group.

ATS/IDSA 2019 CAP guidance recommends abandoning HCAP as an automatic trigger for broad coverage.

A healthcare contact alone is insufficient to infer MRSA or Pseudomonas infection.

Use locally validated resistance risk factors and microbiologic evidence.

Slide 8 · Why hospital-acquired pneumonia is consequential

It is superimposed on the disease that required hospitalization.

Severe illness and impaired host defenses can limit physiologic reserve.

Potentially resistant nosocomial organisms complicate initial treatment.

Severe disease may progress to respiratory failure or systemic infection.

Pathology link

The same inflammatory exudate causes more harm in a lung with limited functional reserve.

Slide 9 · Susceptibility requires multiple converging factors

Host

Comorbidity, immune suppression, low physiologic reserve

Barrier

Impaired cough, mucociliary clearance or phagocytosis

Exposure

Hospital organisms; Respiratory care or invasive devices

Outcome

Infection, neutrophilic exudate and gas-exchange impairment

Slide 10 · Normal air-space defenses

Simplified cross-section — schematic, not histology

Air-space macrophage phagocytoses organisms

Mucociliary clearance removes airway deposits

Neutrophil recruitment amplifies bacterial killing

Slide 11 · Two complementary antimicrobial defenses

Innate

Mucus traps inhaled organisms.

Cilia move mucus toward larger airways.

Alveolar macrophages remove air-space organisms.

Neutrophils arrive during inflammatory recruitment.

Adaptive

Secretory IgA inhibits epithelial attachment.

IgG can opsonize organisms in alveolar lining fluid.

Antibodies activate complement.

T cells support control of intracellular pathogens.

Slide 12 · From alveolar macrophage to neutrophil

Recognition

Resident macrophages encounter an invading organism

Recruitment

Inflammatory mediators attract circulating neutrophils

Clearance

Phagocytosis, opsonization and killing

Injury

Excess exudate limits air-space ventilation

Slide 13 · Systemic vulnerabilities in hospitalized patients

Serious underlying disease

Reduced respiratory reserve and multiple overlapping risk factors.

Immunosuppression

Lower ability to clear microbes and control replication.

Leukopenia or impaired neutrophil function

A weaker acute response to pyogenic bacteria.

Prolonged antibiotic exposure

Selection pressure changes resident microbial ecology and resistance risks.

Slide 14 · Loss of cough permits downward movement of secretions

Depressed consciousness, anesthesia, neuromuscular disorders and drugs reduce protective cough.

Oral and pharyngeal material may more readily enter lower respiratory airways.

Impaired cough works together with retained secretions and poor mucociliary transport.

Aspiration is a potential route, not a synonym for every hospital-onset pneumonia.

Slide 15 · Retention of secretions increases local infection risk

Bronchial obstruction and mucociliary dysfunction hamper microbial clearance.

Viral epithelial damage, tobacco smoke and corrosive exposures can impair cilia.

Static secretions permit organisms to persist near respiratory epithelium.

Small-airway plugging may worsen regional atelectasis and ventilation.

Slide 16 · Mechanical ventilation creates several vulnerabilities

Artificial airway

Bypasses upper-airway defenses

Impaired clearance

Cough and secretion handling are altered

Hospital exposure

Device and care-related microbial encounters

VAP risk

High-risk setting for nosocomial bacterial infection

Slide 17 · Hospital environments add exposure opportunities

Close contact

More opportunities for organisms to spread between patients and settings.

Invasive access

Tubes, catheters and procedures can breach normal barriers.

Respiratory equipment

Contamination can introduce organisms into care pathways.

Antibiotic selection

Hospital flora may show resistance following antibiotic pressure.

Slide 18 · Conceptual pathogenesis of nosocomial bacterial pneumonia

Entry

Organisms reach lower airways

Persistence

Airway/alveolar clearance is insufficient

Host response

Neutrophilic inflammation fills air spaces

Clinical syndrome

Consolidation, oxygenation decline, systemic response

Not every infiltrate represents an infectious process.

Slide 19 · HAP often overlays another clinical disorder

Many hospitalized patients have cardiopulmonary, neurologic or systemic comorbid disease.

Pulmonary edema, atelectasis and pre-existing lung injury can coexist with pneumonia.

Baseline fever, laboratory abnormalities and infiltrates complicate recognition.

Assess the change from the patient’s prior condition.

Slide 20 · The core pathogen spectrum

Organism group

Named examples

Teaching significance

Gram-positive cocci

Staphylococcus aureus

Major cause of HAP; resistant isolates possible

Enterobacteriaceae

Klebsiella spp.; Serratia marcescens; Escherichia coli

Enteric gram-negative rods; susceptibility varies

Nonfermenting gram-negative rods

Pseudomonas species

Especially relevant to nosocomial/VAP settings

Slide 21 · Staphylococcus aureus: Clinically important HAP pathogen

A major gram-positive organism’s HAP spectrum.

May cause severe suppurative pneumonia with necrotizing complications.

Prior influenza infection is another recognized setting for staphylococcal pneumonia.

Organism identification and susceptibility testing guide treatment.

Slide 22 · MRSA: A resistance phenotype, not a microscopic diagnosis

MRSA means methicillin-resistant Staphylococcus aureus.

Methicillin-resistant isolates in nosocomial pneumonia.

Routine H&E tissue morphology cannot establish methicillin resistance.

Resistance information requires appropriate microbiologic testing.

Diagnostic distinction

S. Aureus can produce a suppurative pattern; MRSA requires a microbiologic resistance determination.

Slide 23 · Pseudomonas aeruginosa in hospital-onset infection

A prominent gram-negative rod among hospital-acquired pathogens.

The parent chapter describes susceptibility in neutropenic and immunocompromised patients.

Vascular invasion and extrapulmonary spread are recognized potential consequences.

Empirical coverage depends on illness severity and local susceptibility data.

Slide 24 · Enteric gram-negative rods: A shared pathogen group

Klebsiella spp., Serratia marcescens and Escherichia coli.

These are distinct species with potentially different antibiotic susceptibilities.

Their shared gram-negative rod morphology does not identify the species.

Clinical cultures link a morphologic syndrome to an actionable etiologic diagnosis.

Slide 25 · Klebsiella pneumoniae: Capsule and suppuration

The parent chapter links Klebsiella pneumonia with debilitating illness.

Abundant capsular polysaccharide produces thick, mucoid secretions.

The organism can cause acute, potentially necrotizing bacterial pneumonia.

A classic description should not substitute for species identification.

Slide 26 · Serratia and Escherichia coli: Species matters

Both are included’ hospital-acquired gram-negative list.

Species names describe probable etiology, not a unique H&E pattern.

Gram-stain morphology alone cannot reliably distinguish these organisms.

Culture, identification and susceptibility testing determine the microbiologic diagnosis.

Slide 27 · VAP: Similar organisms, somewhat different distribution

S. Aureus and gram-negative bacilli remain major causes.

Gram-negative bacilli are somewhat more common in VAP.

No universal organism percentage should be assumed from this statement.

Unit-level microbiology is important because distribution changes by hospital.

Slide 28 · A pathogen list is not a hospital antibiogram

Textbook identifies

Local data must determine

Likely genera and species

Which organisms currently dominate an individual unit

Possible resistance phenotype

Susceptibility proportions in that specific institution

Potential complications

How local outcomes vary by patient and organism

Broad syndromic differential

Selection of initial coverage appropriate to that patient

Slide 29 · Resistance and tissue virulence are different axes

Resistance

Determines which antimicrobials may fail.

Demonstrated by susceptibility or resistance testing.

Does not have a distinctive routine H&E signature.

Tissue virulence

Reflects invasion, toxin effects and host response.

Contributes to necrosis, exudate and abscess risk.

Cannot be inferred reliably from resistance status alone.

Slide 30 · Acute bacterial pneumonia: Exudate fills air spaces

Simplified cross-section — schematic, not histology

Acute bacterial infection attracts neutrophils

Protein-rich exudate occupies air spaces

Air-space filling creates consolidation

Slide 31 · Bronchopneumonia: A patchy anatomic distribution

Scattered foci of suppurative consolidation rather than uniform lobar involvement.

Frequently bilateral, multilobar and accentuated in dependent regions.

Lesions may become confluent, obscuring neat anatomic distinctions.

The pattern is descriptive; It cannot identify the causative microbe.

Slide 32 · Bronchiolocentric foci: A simplified distribution

Simplified cross-section — schematic, not histology

Patchy air-space inflammation centered on bronchioles

Individual foci may coalesce into larger areas

Schematic distribution; Not a patient specimen

Slide 33 · Microscopic bronchopneumonia: What to look for

Neutrophil-rich exudate involving bronchi and bronchioles.

Adjacent alveolar air spaces contain inflammatory cells and fluid.

Suppurative foci may be unevenly distributed across sampled parenchyma.

A tissue sample demonstrates the injury pattern; Etiology still requires correlation.

Microscopic signature

Neutrophilic bronchiolitis plus intra-alveolar neutrophils is consistent with acute suppurative bronchopneumonia.

Slide 34 · Lobar pneumonia versus bronchopneumonia

Lobar pneumonia

Consolidation of a large part or all of a lobe.

Classic red and gray hepatization sequence.

Can be caused by several bacterial organisms.

Bronchopneumonia

Patchy consolidations centered on small airways.

Often multilobar or basal with possible confluence.

Cannot define HAP versus CAP by morphology alone.

Slide 35 · The classic stages of lobar pneumonia

Congestion

Engorged capillaries; Alveolar edema and bacteria

Red hepatization

Neutrophils, erythrocytes and fibrin fill alveoli

Gray hepatization

Red-cell breakdown with persistent exudate

Resolution

Digestion and clearance or organization of exudate

These textbook stages describe lobar pneumonia generally, not obligatory stages of HAP.

Slide 36 · Why exudate produces pulmonary consolidation

Normal

Air-filled alveoli enable ventilation

Inflammation

Fluid and neutrophils occupy alveolar lumina

Consolidation

Air spaces become relatively airless and dense

Clinical effect

Auscultation, imaging and gas exchange change

Slide 37 · How pneumonia contributes to hypoxemia

Patchy injury

Some alveoli become poorly ventilated

Perfusion

Blood flow may persist through affected units

Mismatch

Ventilation/perfusion disparity increases

Result

Oxygenation declines; Respiratory effort may rise

Schematic functional explanation; Severity depends on extent and baseline disease.

Slide 38 · Clinical clues: Assess a change from baseline

New or progressive respiratory symptoms and secretions.

Fever or a new inflammatory response, interpreted against competing causes.

New or worsening pulmonary opacity on imaging.

Deteriorating oxygenation or increasing respiratory support needs.

Slide 39 · Clues in mechanically ventilated patients

Increased or newly purulent endotracheal secretions.

New or progressive infiltrates paired with an infectious clinical picture.

Fever, leukocytosis or worsening oxygenation may increase suspicion.

No single sign establishes VAP: Alternatives can mimic each component.

Slide 40 · Radiographic patterns need clinical correlation

Appearance

Compatible process

Important limitation

Focal patchy opacity

Bronchopneumonia or atelectatic change

Opacity alone does not prove infection

Confluent lobar opacity

Extensive air-space consolidation

Organism cannot be identified radiographically

Bilateral multifocal opacities

Multifocal infection or edema/acute lung injury

Distribution is not etiologically specific

Slide 41 · Syndromic diagnosis: Combine independent evidence

Time & risks

Hospital or ventilator timeline; Host factors

Clinical

Temperature, secretions, oxygenation and symptoms

Imaging

New/progressive parenchymal infiltrate

Microbiology

Appropriate respiratory culture when obtainable

Reassess if an alternative noninfectious explanation is stronger.

Slide 42 · There is no single gold standard for HAP or VAP

The ATS/IDSA 2016 guideline explicitly notes diagnostic uncertainty.

A new radiographic infiltrate is not specific for infection.

Positive respiratory cultures can reflect airway colonization.

Clinical probability depends on converging findings and disease course.

Slide 43 · Respiratory sampling answers etiologic questions

Identify the pathogen, when possible, from an appropriate respiratory specimen.

Evaluate sample quality and possible contamination or colonization.

Use microbiologic data alongside clinical suspicion rather than as a substitute.

Obtain susceptibility results to support focused antimicrobial therapy.

Slide 44 · Why a positive culture can mislead

Colonization

An organism may be present without causing invasive pneumonia.

Specimen quality

Upper-airway contamination may complicate organism attribution.

Prior antibiotics

Sampling after therapy can alter organism recovery.

Discordance

Culture, imaging and clinical response may point in different directions.

Slide 45 · VAP: Noninvasive sampling is often adequate

ATS/IDSA 2016 suggests endotracheal aspiration with semiquantitative culture for suspected VAP.

The recommendation was weak and supported by low-quality evidence.

Invasive quantitative culture methods have not shown clear outcome superiority.

Local protocols and the patient’s clinical condition still matter.

Slide 46 · Histology describes injury, not acquisition setting

Neutrophilic air-space inflammation establishes a suppurative tissue response.

Neither H&E morphology nor gross distribution can define “hospital acquired.”

Culture or molecular testing may identify the responsible microorganism.

Temporal and clinical context is required to diagnose HAP or VAP.

Slide 47 · Major complication pathways

Local injury

Neutrophil-rich inflammation and necrosis

Necrotic focus

Abscess or cavitating suppuration

Pleural spread

Empyema and pleural organization

Bloodstream spread

Metastatic suppurative foci and sepsis

Outcomes are potential pathways; Not a universal sequence.

Slide 48 · Lung abscess: Localized destructive suppuration

Destruction of lung parenchyma creates a cavity containing purulent material.

Necrotizing complications with several pyogenic organisms.

S. Aureus and Klebsiella are among clinically important causes.

An abscess represents a complication, not a defining requirement of HAP.

Slide 49 · Empyema: Infection extends to the pleural cavity

Spread of bacterial inflammation to the pleural space can produce pus.

The pleural response is fibrinosuppurative rather than purely intra-alveolar.

Organization may lead to fibrous thickening and adhesions.

Pleural involvement may alter both clinical findings and treatment needs.

Slide 50 · Bacteremic dissemination produces distant complications

Pulmonary infection may lead to bloodstream dissemination of organisms.

Potential seeding of heart valves, pericardium, brain, kidneys and joints.

Examples include endocarditis, meningitis and metastatic abscesses.

Evaluate for systemic infection when clinical severity is disproportionate.

Slide 51 · Noninfectious mimics of suspected hospital pneumonia

Mimic

Overlapping finding

Discriminating question

Atelectasis

New opacity and oxygenation decline

Is there volume loss or airway obstruction?

Pulmonary edema

Bilateral opacities and hypoxemia

Does fluid balance or cardiac dysfunction explain the picture?

Acute lung injury

Diffuse opacities and respiratory failure

Is there an alternative inflammatory insult?

Aspiration injury

Acute dependent opacities

Was aspiration temporally evident?

Slide 52 · Aspiration pneumonitis versus HAP

Aspiration process

Entry of gastric or oropharyngeal material.

Chemical injury may precede bacterial infection.

May occur during hospitalization but has its own mechanism.

Hospital-acquired bacterial pneumonia

Infection developing after hospital exposure.

Hospital flora and impaired defenses are central.

Overlap can occur; Use chronology and microbiology.

Slide 53 · CAP versus HAP: What the setting changes

Community-acquired pneumonia

Acquired outside hospital or present at admission.

Community epidemiology guides initial differential.

Can still be caused by resistant organisms in selected patients.

Hospital-acquired pneumonia

Develops ≥48 hours after hospital admission.

Nosocomial pathogens and resistance are of greater concern.

Hospital-unit antibiograms can guide empiric choices.

Slide 54 · Antimicrobial stewardship has two directions

At presentation

Act on credible severe bacterial infection

Initial regimen

Account for severe illness and local resistance risks

New evidence

Review clinical trajectory and organism data

Narrow therapy

De-escalate when appropriate; Avoid needless broad coverage

Slide 55 · Empirical treatment is a risk-adapted clinical choice

Initial therapy is guided by severity, organism likelihood and local antibiograms.

S. Aureus and relevant gram-negative bacilli need consideration in HAP.

MRSA and resistant Pseudomonas coverage is guided by validated risk and local susceptibility.

Avoid treating all hospital-exposed patients as identically resistant.

Slide 56 · De-escalation and treatment duration

ATS/IDSA 2016 suggests de-escalation rather than fixed broad-spectrum treatment.

A 7-day antibiotic course is recommended for VAP and HAP in uncomplicated improving cases.

Shorter or longer treatment may be appropriate with different rates of recovery or complications.

Reassess clinical status, cultures and competing diagnoses throughout treatment.

Slide 57 · Preventable links in the causal chain

Exposure control

Use infection-prevention practices to limit cross transmission.

Device necessity

Reassess invasive respiratory support and device need.

Airway care

Maintain safe secretion management and respiratory equipment practices.

Antibiotic review

Avoid unnecessary exposure that selects resistant flora.

Slide 58 · Case 1 — new infiltrate after admission

A patient with severe heart failure develops fever, purulent sputum, a new patchy opacity and increasing oxygen requirement on hospital day 5. The patient has not been mechanically ventilated.

Discussion prompts

Which timing category best describes the syndrome?

Name two noninfectious alternatives to assess.

What sampling or clinical evidence could strengthen causation?

Slide 59 · Case 1 — structured interpretation

HAP is a plausible clinical syndrome: Non-ventilated hospital day 5 with new compatible findings.

Pulmonary edema and atelectasis remain competing explanations for opacity and hypoxemia.

Interpret respiratory cultures with specimen quality and overall infection probability.

Empiric decisions require severity assessment and local susceptibility data.

Slide 60 · Case 2 — deteriorating oxygenation during ventilation

An intubated ICU patient has been ventilated for 6 days. Oxygen requirement rises, secretions become purulent and imaging shows new multifocal opacities. Endotracheal aspirate grows a gram-negative bacillus.

Discussion prompts

Which pneumonia category should be considered?

Does the culture alone prove invasive infection?

How should final organism identification affect therapy?

Slide 61 · Case 2 — structured interpretation

VAP is a consideration because the new syndrome developed >48 hours after intubation.

Endotracheal growth may reflect either infection or colonization; Correlate all findings.

Gram-negative bacilli are common in VAP; Species and susceptibility remain essential.

Reassess the diagnosis and de-escalate treatment when appropriate.

Slide 62 · Integrated diagnostic reasoning map

Detect

New clinical + imaging abnormality

Classify

HAP, VAP or competing syndrome

Sample

Respiratory culture and relevant evaluation

Reassess

Course, susceptibility, alternate causes and complications

A clinical pathway for teaching; Not a universal prescription.

Slide 63 · What should be retained from this lecture?

Timing and mechanical ventilation distinguish HAP from VAP in ATS/IDSA usage.

Host defenses, devices and exposure together determine risk.

S. Aureus and gram-negative bacilli dominate the textbook pathogen spectrum.

Suppurative bronchopneumonia is a common pattern, but morphology is not etiologic proof.

Clinical diagnosis requires correlation; Culture and local antibiograms support stewardship.

Slide 64 · Selected source literature

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Elsevier; 2026. Ch. 15, The Lung, pp. 643–649.

Kalil AC, et al. Management of adults with HAP and VAP: 2016 IDSA/ATS clinical practice guidelines. Clin Infect Dis. 2016;63:e61–e111. doi:10.1093/cid/ciw353.

Metlay JP, et al. Diagnosis and treatment of adults with CAP: 2019 ATS/IDSA guideline. Am J Respir Crit Care Med. 2019;200:e45–e67. doi:10.1164/rccm.201908-1581ST.

No textbook micrographs reproduced; morphology visuals are original conceptual schematics.